# A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics

> **NCT05607199** · PHASE1 · TERMINATED · sponsor: **Aurigene Discovery Technologies Limited** · enrollment: 27 (actual)

## Conditions studied

- Solid Tumor, Adult
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
- Non Hodgkin Lymphoma

## Interventions

- **DRUG:** AUR103

## Key facts

- **NCT ID:** NCT05607199
- **Lead sponsor:** Aurigene Discovery Technologies Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-09-16
- **Primary completion:** 2024-11-27
- **Final completion:** 2024-11-27
- **Target enrollment:** 27 (ACTUAL)
- **Why stopped:** Patient recruitment problems.
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05607199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05607199, "A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05607199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*